Related Experiment Video

Updated: Jul 12, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

The Association Between Mild Cognitive Impairment and Medication Non-adherence Among Elderly Patients With Chronic

Xiaoqin He1,2, Xinguo Wang1,2, Bin Wang3

  • 1School of Graduate, Shanghai University of Traditional Chinese Medicine, Shanghai, CHN.

Cureus
|October 30, 2023
PubMed
Abstract

Insights

Mild cognitive impairment (MCI) significantly increases medication non-adherence in elderly patients. Early identification and intervention for MCI are crucial for improving treatment outcomes in this population.

Area of Science:

  • Gerontology
  • Neurology
  • Pharmacology

Background:

  • Medication adherence is critical for elderly patients managing multiple chronic conditions.
  • Mild cognitive impairment (MCI) is common in the elderly, but its effect on medication adherence is not fully understood.

Purpose of the Study:

  • To investigate the impact of mild cognitive impairment (MCI) on medication adherence in elderly patients with chronic diseases.

Main Methods:

  • A cross-sectional study involving 436 elderly patients (≥60 years) with chronic diseases.
  • Medication adherence assessed using the Morisky Medication Adherence Scale-8 (MMAS-8).
  • Mild cognitive impairment (MCI) screened using the Mini-Mental State Examination (MMSE); multivariate logistic regression used.

Main Results:

  • 48.6% of patients exhibited poor medication compliance; 41.5% had MCI.
  • MCI was significantly associated with medication non-adherence (OR=3.95).
  • MCI remained an independent risk factor for non-adherence (aOR=2.64); adverse drug reactions and poor medication effect evaluation were also significant.

Conclusions:

  • Mild cognitive impairment (MCI) substantially and independently impacts medication non-adherence in elderly patients.
  • Early identification of MCI and targeted interventions are essential for improving medication adherence and health outcomes.
Keywords:
chronic diseaseselderlyinfluential factormedication adherencemild cognitive impairment

More Related Videos

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit06:52

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit

Published on: September 30, 2020

9.8K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.4K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
47
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
120
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
125